{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T02:48:21Z","timestamp":1790390901892,"version":"4.1.0"},"reference-count":18,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2002,11,1]],"date-time":"2002-11-01T00:00:00Z","timestamp":1036108800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,1,7]],"date-time":"2020-01-07T00:00:00Z","timestamp":1578355200000},"content-version":"vor","delay-in-days":6276,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2002,11]]},"DOI":"10.1093\/annonc\/mdf284","type":"journal-article","created":{"date-parts":[[2002,11,6]],"date-time":"2002-11-06T21:18:48Z","timestamp":1036617528000},"page":"1737-1742","source":"Crossref","is-referenced-by-count":60,"title":["Neoadjuvant chemotherapy with a combination of pegylated liposomal doxorubicin (Caelyx\u00ae) and paclitaxel in locally advanced breast cancer: a phase II study by the Hellenic Cooperative Oncology Group"],"prefix":"10.1016","volume":"13","author":[{"given":"H.","family":"Gogas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Papadimitriou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.P.","family":"Kalofonos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Bafaloukos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Fountzilas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Tsavdaridis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Anagnostopoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Onyenadum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Papakostas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Economopoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Christodoulou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Kosmidis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Markopoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1093\/annonc\/mdf284_bb0010","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1016\/S0959-8049(05)80122-4","article-title":"Systemic treatment for locally advanced breast cancer. What we still need to learn after a decade of multimodality clinical trials","volume":"28","author":"Piccart","year":"1992","journal-title":"Eur J Cancer"},{"key":"10.1093\/annonc\/mdf284_bb0015","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.1200\/JCO.1995.13.7.1777","article-title":"Liposomal doxorubicin antitumor activity and unique toxicities during two complementary phase I studies","volume":"13","author":"Uziely","year":"1995","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdf284_bb0020","doi-asserted-by":"crossref","first-page":"3185","DOI":"10.1200\/JCO.1997.15.10.3185","article-title":"Treatment of advanced breast cancer with sterically stabilized lipoosomal doxorubicin. Results of a multicenter phase II trial","volume":"15","author":"Ranson","year":"1997","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdf284_bb0025","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1080\/07357909909011727","article-title":"Taxanes in the treatment of breast cancer: a prodigy comes of age","volume":"17","author":"Miller","year":"1999","journal-title":"Cancer Invest"},{"key":"10.1093\/annonc\/mdf284_bb0030","first-page":"107a","article-title":"Paclitaxel: an angiogenesis antagonist in a metastatic breast cancer model","volume":"17","author":"Lau","year":"1998","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1093\/annonc\/mdf284_bb0035","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1200\/JCO.1995.13.5.1152","article-title":"Paclitaxel as second and subsequent therapy for metastatic breast cancer: activity independent of prior anthracycline response","volume":"13","author":"Seidman","year":"1995","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdf284_bb0040","doi-asserted-by":"crossref","first-page":"2056","DOI":"10.1200\/JCO.1995.13.8.2056","article-title":"Paclitaxel activity in heavily pretreated breast cancer: a National Cancer Institute Treatment Referral Center trial","volume":"13","author":"Abrams","year":"1995","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdf284_bb0045","doi-asserted-by":"crossref","first-page":"1943","DOI":"10.1200\/JCO.1993.11.10.1943","article-title":"Paclitaxel and recombinant human granulocyte colony-stimulating factor as initial chemotherapy for metastatic breast cancer","volume":"11","author":"Reichman","year":"1993","journal-title":"J Clin Oncol"},{"key":"10.1093\/annonc\/mdf284_bb0050","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1093\/jnci\/83.24.1797-a","article-title":"Phase II trial of taxol, an active drug in the treatment of metastatic breast cancer","volume":"83","author":"Holmes","year":"1991","journal-title":"J Natl Cancer Inst"},{"key":"10.1093\/annonc\/mdf284_bb0055","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/0959-8049(95)00398-3","article-title":"A phase II study of paclitaxel in advanced breast cancer resistant to anthracyclines","volume":"32A","author":"Fountzilas","year":"1996","journal-title":"Eur J Cancer"},{"issue":"Abstr 281","key":"10.1093\/annonc\/mdf284_bb0060","first-page":"17","article-title":"Prevention and management of DOXIL-related side effects: basic strategies","volume":"72a","author":"Yee","year":"1998","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1093\/annonc\/mdf284_bb0065","first-page":"160a","article-title":"Phase II randomized trial of doxorubicin HCI liposome injection (Doxil) plus paclitaxel (DT) in metastatic breast cancer","volume":"17","author":"Moore","year":"1998","journal-title":"Proc Am Soc Clin Oncol"},{"issue":"Suppl 17","key":"10.1093\/annonc\/mdf284_bb0070","first-page":"1710","article-title":"Pilot study of primary chemotherapy with doxorubicin plus paclitaxel in women with locally advanced or operable breast cancer","volume":"24","author":"Moliterni","year":"1997","journal-title":"Semin Oncol"},{"issue":"Abstr 25","key":"10.1093\/annonc\/mdf284_bb0075","first-page":"50","article-title":"A randomized, parallel study of doxorubicin\/Taxol (paclitaxel) (AT) and doxorubicin\/ cyclophosphamide (AC) as neoadjuvant treatment of breast cancer","volume":"233","author":"Dieras","year":"1998","journal-title":"Breast Cancer Res Treat"},{"issue":"Abstr 508","key":"10.1093\/annonc\/mdf284_bb0080","first-page":"69","article-title":"A randomized study of 4 versus 6 cycles of adriamycin\u2013taxol as neoadjuvant treatment of breast cancer","volume":"298","author":"Fumoleau","year":"2001","journal-title":"Breast Cancer Res Treat"},{"key":"10.1093\/annonc\/mdf284_bb0085","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1002\/1097-0142(20000901)89:5<1037::AID-CNCR13>3.0.CO;2-Z","article-title":"Correlation of toxicity with pharmacokinetics of pegylated liposomal doxorubicin (Doxil)","volume":"89","author":"Lyass","year":"2000","journal-title":"Cancer"},{"key":"10.1093\/annonc\/mdf284_bb0090","doi-asserted-by":"crossref","first-page":"2688","DOI":"10.1200\/JCO.1995.13.11.2688","article-title":"Paclitaxel by 3-hour infusion in combination with bolus doxorubicin in women with untreated metastatic breast cancer: high antitumor efficacy and cardiac effects in a dose-finding and sequence-finding study","volume":"13","author":"Gianni","year":"1995","journal-title":"J Clin Oncol"},{"issue":"Abstr 128","key":"10.1093\/annonc\/mdf284_bb0095","first-page":"15","article-title":"Efficacy and cardiac effects of 3-h paclitaxel plus bolus doxorubicin in women with untreated metastatic breast cancer","volume":"116","author":"Gianni","year":"1996","journal-title":"Proc Am Soc Clin Oncol"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419637233?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419637233?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/academic.oup.com\/annonc\/article-pdf\/13\/11\/1737\/532338\/mdf284.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,2,20]],"date-time":"2020-02-20T02:32:42Z","timestamp":1582165962000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753419637233"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2002,11]]},"references-count":18,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2002,11]]}},"alternative-id":["S0923753419637233"],"URL":"https:\/\/doi.org\/10.1093\/annonc\/mdf284","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2002,11]]}}}